Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Punica granatum pleniflora, known in Persian traditional medicine as Golnar, is a specific variety of pomegranate characterized by its sterile, double-petaled flowers. Unlike the fruit-bearing pomegranate, this variety is cultivated primarily for its medicinal properties. As a therapeutic agent, it is typically prepared as an aqueous extract or mouth rinse. It is rich in bioactive secondary metabolites, particularly tannins (such as punicalagin and ellagic acid) and polyphenols, which confer potent astringent, anti-inflammatory, and antimicrobial activities. In clinical settings, it has been investigated for its ability to manage oral health conditions, specifically gingivitis in diabetic patients, by reducing dental plaque accumulation and gingival inflammation. Its mechanism involves the precipitation of proteins and the inhibition of periodontal pathogens and pro-inflammatory mediators.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on punica granatum pleniflora.